Introduction: Active hexose correlated compound (AHCC) is an alfa-glucan nutritional supplement made from the mycelia of Lentinula edodes mushroom. Human clinical studies have shown that AHCC significantly improves immune response, increases normal NK cell activity and enhances macrophage and T‑cell activity.
Aim(s): To assess the efficacy of AHCC to protect the immunological system in neuroendocrine tumor (NET) patients after 90Y-DOTA-TATE therapy.
Materials and methods: We evaluated three patients with confirmed NETs. Patients were treated with four doses of 90Y-DOTA-TATE (3.7 GBq/m2 /dose) in 8-10 week intervals (median dose 14,8 Gbq/m2 per patient). Control computed tomography and PET/CT with somatostatin analog 68Ga-DOTA-TATE were conducted three months after the last dose of 90Y-DOTA-TATE. Patients took AHCC in the amount of 3 × 2 g daily, 40 min before meals. Immunological toxicity has been compared with nine patients summarised by Sierra study. In the Italian group, the average dose of 90Y-DOTA-TOC was 5.5 GBq per patient.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Norbert Szaluś
To read results and conclusion, please login ...
Further abstracts you may be interested in